StockData
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. (MBRX) company profile

MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$6.75−0.08 (-1.17%)

Close on Nov 18, 2026Market cap $131.47MP/E –Yield –

About Moleculin Biotech

Pharmaceutical Preparations, SIC 2834

Moleculin Biotech is a late-stage pharmaceutical development company focused on creating treatments for hard-to-treat oncology indications and viruses. The company's lead drug candidate is Annamycin, a next-generation anthracycline designed to avoid cardiotoxicity and bypass multidrug resistance mechanisms. Its clinical pipeline also includes the WP1066 program targeting glioblastoma and other brain tumors, as well as the WP1122 portfolio of glycolysis inhibitors. Core clinical candidates serve patient populations with acute myeloid leukemia, soft tissue sarcoma lung metastases, and pediatric brain cancers.

The company operates internationally, coordinating research and clinical programs across academic institutions and medical centers in the United States and Europe. Its clinical trials include multi-center evaluations spanning over twenty sites across nine countries, such as Poland, Italy, and the United States. Key preclinical and development collaborations take place in conjunction with the University of Texas MD Anderson Cancer Center in Houston, Texas. Moleculin Biotech does not specify its corporate headquarters location in the provided text.

Summary of the business section of Moleculin Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Moleculin Biotech, Inc.
Headquarters
Houston, TX
Address
5300 Memorial Drive, Suite 950 77007
Phone
(713) 300-5160
Employees
150,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Fort Lauderdale, Florida

Stock & identifiers

Ticker
MBRX
Exchange
Nasdaq
IPO date
May 3, 2016
Shares outstanding
19M, Aug 6, 2026
Public float
$8.80M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Oct 20, 2026; 1-for-25 reverse, Dec 1, 2025; 1-for-15 reverse, Mar 22, 2024; 1-for-6 reverse, Feb 1, 2021
SEC CIK
1659617
CUSIP
60855D408
ISIN
US60855D4088
FIGI
BBG00B9T47L9
Share class FIGI
BBG00B9T47N7
LEI
549300IB1TLJZCHEO353
EIN
47-4671997

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Walter V. KlempCEO and President, Director1,111,545
Jonathan P. FosterChief Financial Officer20,506
Donald H. PickerChief Science Officer560,718
John M. ClimacoDirector–
Michael D. CannonDirector–
Robert E. GeorgeDirector14,660
Elizabeth CermakDirector–
Joy YanDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.35M$722.26K$765.09K$1–
FY2024$1.46M$339.60K$841.85K$11–
FY2023$1.41M$1.44M$719.87K$81–
FY2022$1.97M$1.46M$895.86K$22–
FY2021$1.99M$754.19K$915.79K$39–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Walter V. Klemp
Chairman, President - Chief Executive Officer
$565.00K$324.89K$426.75K$29.32K$1.35M-8%
Jonathan P. Foster
Executive Vice President and Chief Financial Officer
$405.00K$234.86K$227.60K$39.81K$907.27K-8%
Donald Picker
Chief Scientific Officer
$340.00K$78.23K$182.08K$22.61K$622.92K-10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 3, 2016
Offer price
$6.00
Securities offered
2,000,000
Gross proceeds
$12.00M
Exchange
Nasdaq
Lock-up ends (est.)
Oct 30, 2016

“The initial public offering price per share will be $6.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“There are approximately 150,000 people with AML worldwide with over 20,000 newly diagnosed patients annually in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?